Silver Book Fact

Survival rates for colon cancer went from 41 percent to 63 percent between 1975 and 1995.

Lichtenberg F. The Expanding Pharmaceutical Arsenal in the War on Cancer. National Bureau of Economic Research. February 2004; Working Paper No. 10328. http://www.nber.org/papers/w10328

Reference

Title
The Expanding Pharmaceutical Arsenal in the War on Cancer
Publication
National Bureau of Economic Research
Publication Date
February 2004
Authors
Lichtenberg F
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.  
  • Every additional dollar spent on newer, less toxic hormonal therapy for breast cancer patients has produced health gains valued at between $27.03 and $36.81.  
  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become…  
  • Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months…